Co-Diagnostics

CODX

Market cap $4.94M

SALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has been strengthening its distributor base across India, recently attending and participating in two regional conferences.

CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.

SALT LAKE CITY , Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR).

SALT LAKE CITY , Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reactivity of the primer sets against the influenza A H3N2 subclade K.

SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA. The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will unpack Co-Dx's move to portable PCR diagnostics to address evolving point-of-care needs, introduce the Company's upcoming Co-Dx PCR platform* and intuitive smartphone interface, and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.

Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture ("JV") between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India.

CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SALT LAKE CITY , Nov. 20, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company's Executive Vice President of Business Development, Joseph Featherstone, addressed a satellite session of the International Union Against Tuberculosis and Lung Disease (The Union) 2025 World Conference on Lung Health earlier today in Copenhagen, Denmark, in a talk providing industry perspective on adoption and implementation of a tuberculosis molecular diagnostic test. For over 100 years, The Union World Conference on Lung Health has come together to present the latest scientific research in all aspects of lung health.

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has begun clinical evaluations for its Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit. The clinical performance testing is expected to support a submission to the United States Food and Drug Administration ("FDA") for 510(k) clearance of the upper respiratory multiplex point-of-care test, and the Co-Dx PCR Pro™* instrument.

Co-Diagnostics, Inc. ( CODX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman & CEO Brian Brown - CFO & Company Secretary Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.